# Tirzepatide + BPC-157 blend

Source: https://aminodesk.com/library/tirzepatide-bpc-157
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

This blend combines tirzepatide and BPC-157 in one product. It is sold for weight loss with fewer stomach side effects. The claim that BPC-157 eases tirzepatide's stomach side effects has not been tested, and no approved product combines them.

- **Legal lane:** not an approved product. Tirzepatide alone is FDA-approved; the mixture is not.
- **Evidence grade:** D for the combination
- **What is in it:** tirzepatide and BPC-157
- **Established human dose:** none

## What it is

A premixed product sold by peptide suppliers and some clinics. The ingredients:

- **[tirzepatide](https://aminodesk.com/library/tirzepatide):** an FDA-approved drug, sold as Mounjaro and Zepbound.
- **[BPC-157](https://aminodesk.com/library/bpc-157):** one of the six peptides in the October 2026 policy; almost all of its evidence is from animals.

## What the evidence shows

We found no trial of this combination. The evidence that exists applies to each ingredient studied on its own, and each ingredient's page has its grade and what was shown.

Tirzepatide's results come from large trials of tirzepatide alone, at set doses with a slow step-up. Nobody has tested whether adding BPC-157 reduces nausea, and nobody has checked whether mixing the two in one vial affects either one.

## Legal status

In October 2026, HHS issued an interim policy allowing licensed pharmacies to compound six peptides on prescription: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. One condition is that the compounded product contains a single active ingredient from that list. Law firms that analyzed the policy concluded that products with more than one active ingredient fall outside it.

BPC-157 is on the list, but only as a single-ingredient product. Tirzepatide is an approved brand-name drug. A vial that mixes them is neither the approved drug nor a product the policy covers.

## Reported dosing

**No dose has been established for this blend.**

No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown.

## Safety

- If you improve, you cannot tell which ingredient did it. If you react, you cannot tell which one caused it.
- The ratio is fixed by the seller. You cannot adjust one ingredient without moving the other.
- No safety or absorption work exists on the mixture.
- With a mixed vial, raising or lowering the tirzepatide dose changes the BPC-157 dose with it.
- The approved pens have verified contents and a label. A mixed vial has neither.
- Side effects on tirzepatide are best handled with the prescriber, usually by slowing the step-up.

## Common questions

### What is in this blend?

Tirzepatide and BPC-157.

### Has this blend been tested in people?

We found no human trial of the combination.

### Is this blend legal?

No approved product combines them. Tirzepatide is available by prescription on its own.

## Sources

- [HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf)
- [McDermott Will & Emery: the conditions exclude multiple-ingredient compounded products](https://www.mcdermottlaw.com/insights/peptides-first-paperwork-later-hhs-clears-six-for-compounding-ahead-of-bulks-list-rulemaking/)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
